drugset
drugset / Trial / NCT02068794

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT02068794 ↗

Phase 1/2 Active not recruiting 34 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.

Timeline

Start
2014-04-25
Primary completion
2024-03-15
Completion
2026-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MV-NIS Unknown — Other

Indications

fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube mucinous adenocarcinoma fallopian tube serous adenocarcinoma fallopian tube transitional cell carcinoma malignant ovarian Brenner tumor ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous adenocarcinoma ovarian seromucinous carcinoma ovarian serous adenocarcinoma ovarian transitional cell carcinoma primary peritoneal serous adenocarcinoma undifferentiated ovarian carcinoma